Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e

Vaccine

Volumn 33, Issue 29, 2015, Pages 3398-3406

  Tsybalova, Liudmila M ^a   Stepanova, Liudmila A ^a   Kuprianov, Victor V ^b   Blokhina, Elena A ^b   Potapchuk, Marina V ^a   Korotkov, Alexander V ^a   Gorshkov, Andrey N ^a   Kasyanenko, Marina A ^a   Ravin, Nikolai V ^b   Kiselev, Oleg I ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b INSTITUTE OF BIOENGINEERING   (Russian Federation)

Author keywords

HBc M2e recombinant vaccine; Immunogenicity; Influenza A; Protective properties

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; M2E RECOMBINANT PROTEIN; PROTEIN M2; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN G; M2 PROTEIN, INFLUENZA A VIRUS; M2E-HBC INFLUENZA VACCINE; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; LUNG LAVAGE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CROSS PROTECTION; DISEASE MODEL; ESCHERICHIA COLI; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; T LYMPHOCYTE; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EPITOPES; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HEPATITIS B CORE ANTIGENS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; LUNG; MICE, INBRED BALB C; MUTAGENESIS, INSERTIONAL; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84931560936     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.073     Document Type: Article

References (32)

1. Smorodincev A.A., Chalkina O.M., Burov C.A. Estimate of epidemiological efficacy live influenza vaccine during influenza outbreak in 1959. Etiology immunology and clinic characteristic of Asian influenza. Transaction of scientific papers. Transaction of the All-Union research institute of influenza 1961, 200-207.
2. Zdanov V.M., Antonova I.A. The Hong Kong influenza virus epidemic in the USSA. Bull WHO 1969, 41:381-385.
3. Wood J.M. Developing vaccines against pandemic influenza. Phil Trans R Soc Lond B 2001, 356:1953-1960.
4. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
5. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69:517-528.
6. Mozdzanowska K., Feng J.Q., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
7. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-436.
8. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
9. Adler-Moore J., Munoz M., Kim H., Romero J., Tumpey T., Zeng H., et al. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 2011, 29:4460-4468.
10. Park K.S., Seo Y.B., Lee J.Y., Song M., et al. Complete protection against a N5N1 avian influenza virus by DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 2011, 29:5481-5487.
11. Petukhova N.V., Gasanova T.V., Stepanova L.A., Rusova O.A., Potapchuk M.V., Korotkov A., et al. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by tobacco mosaic virus-based vectors. Curr Pharm Des 2013, 19:5587-5600.
12. Denis J., Acosta-Ramizez E., Zhao Y., Hamelin M.E., Kouravica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2 peptide fused to the papaya mosaic virus (Pap MV) vaccine platform. Vaccine 2008, 26:3395-3403.
13. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A. Universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
14. Fiers W., De Filette M., Birkett A., Neirynck S., Jou W.M. A 'universal' human influenza A vaccine. Virus Res 2004, 103:173-176.
15. De Filette M., Jou W.M., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337:149-161.
16. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25:763-775.
17. Ravin N.V., Kotlyarov R.Y., Mardanova E.S., Kuprianov V.V., Migunov A.I., Stepanova L.A., et al. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry 2012, 77:33-40.
18. Blokhina E.A., Kuprianov V.V., Syepanova L.A., Tsybalova L.M., Skryabin K.G., Ravin N.V., et al. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology 2013, 435:293-300.
19. Ulrich R., Nassal M., Meisel H., Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998, 50:141-182.
20. Milich D.R., McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986, 234:1398-1401.
21. Tinghua C., Lazdina U., Desombere I., Vanlandschoot P., Milich R.D., Sällberg M., et al. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. Virol J 2001, 75:6359-6366.
22. De Fillete M., Joy W.M., Bessa J., Schmitz N., Hinton H.J., Schwarz K., et al. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implication for vaccine design. Eur J Immunol 2008, 38:114-126.
23. Bachmann M.F., Rohrer U.H., Kündig T.M., Bürki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
24. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
25. Liu X., Guo J., Han S., Yao L., Chen A., Yang Q., et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012, 30:6527-6533.
26. Stanekova Z., Kiraly J., Stropkovska A., Mikuskova T., Mucha V., Kostolansky F., et al. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol 2011, 55(1):61-67.
27. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Virol J 1988, 62:2762-2772.
28. Zou P., Liu W., Chen Y.-H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 2005, 5:631-635.
29. Mozdzanowska K., Maiese K., Furcher M., Gehard W. Treatment of influenza virus-infected SCID mice with non-neutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduced the pulmonary virus titre but fails to clear the infection. Virology 1999, 254:138-146.
30. Mozdzanovska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by asynthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007, 4:118-129.
31. Schmiz N., Beerli R., Bauer M., Jegerhner A., Dietmier K., Maudrich M., et al. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012, 42:863-869.
32. EL Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.